

## Peninsula Energy (PEN)

Rating: Buy | Risk: High | Price Target: \$1.33

19 September 2025

## Lance Reset Produces First Yellowcake

Key Information	
Current Price (\$ps)	0.39
12m Target Price (\$ps)	1.33
52 Week Range (\$ps)	0.28 - 1.56
Target Price Upside (%)	246.6%
TSR (%)	246.6%
Reporting Currency	USD
Market Cap (\$m)	146
Sector	Energy
Avg Daily Volume (m)	7.3
ASX 200 Weight (%)	0%

- 6	ıın	A٠	m	~	nta	l۰

YE 30 Jun (USD)	FY24A	FY25E	FY26E	FY27E
Sales (\$m)	12	0	38	87
NPAT (\$m)	(12)	(23)	(2)	39
EPS (cps)	(0.6)	(1.3)	(8.0)	9.9
EPS Growth (%)	(79.2%)	nm	44.0%	nm
DPS (cps) (AUD)	0.0	0.0	0.0	0.0
Franking (%)	0%	0%	0%	0%

#### Ratios

YE 30 Jun	FY24A	FY25E	FY26E	FY27E
P/E (x)	nm	(18.9)	(33.7)	2.6
EV/EBITDA (x)	(3.4)	(1.7)	13.8	0.9
Div Yield (%)	0.0%	0.0%	0.0%	0.0%
Payout Ratio (%)	0.0%	0.0%	0.0%	0.0%

### **Price Performance**

YE 30 Jun	1 Mth	2 Mth	3 Mth	1 Yr
Relative (%)	(14.6%)	(16.2%)	(18.9%)	(76.6%)
Absolute (%)	(16.3%)	(16.3%)	(16.3%)	(69.8%)
Benchmark (%)	(1.7%)	(0.1%)	2.6%	6.8%



### Andrew Hines | Head of Research

+61 3 9268 1178

andrew.hines@shawandpartners.com.au

## Peter Kormendy | Senior Research Analyst

+61 3 9268 1099

Peter.Kormendy@shawandpartners.com.au

## Dorab Postmaster | Analyst

+61 8 9263 5211

Dorab.Postmaster@shawandpartners.com.au

#### Event

Peninsula Energy has successfully 'reset' the Lance Project and has produced its first  $U_3O_8$  ("yellowcake"). Lance has the potential to become the largest source of domestic uranium production in the US and is therefore a highly strategic asset in the context of the US nuclear fuel supply chain. We resume coverage post the recent A\$70m equity raise which was a key element of the reset plan. We recently visited the Lance Project and came away impressed with the on-site management team and confident that historic issues have been resolved. We upgrade our recommendation to BUY with a A\$1.33 price target.

## **Highlights**

- The Lance Uranium Project is an in-situ leach project in Wyoming, US. The operation has
  recovered from a range of setbacks over the past two years and has now successfully
  produced its first yellowcake. The key elements of the Reset Plan are:
  - Management and Board change: New MD and CEO George Bauk and new CFO Jitu Bhudia have done an excellent job resetting the operation, resetting the contract book and resetting the balance sheet. David Coyne has taken over as Non-Executive Chairman and experienced uranium executive Keith Bowes has joined the board as a Non-Executive Director.
  - A revised production profile: Peninsula is now working to a more conservative mine plan over three time horizons. Horizon 1 is the initial ramp-up period in 2025, Horizon 2 runs over 2026 and 2027 with production increasing to 400-600klbpa and Horizon 3 is full scale production from 2028 of 1.2-1.5Mlbpa. There is growth potential beyond Horizon 3 with the plant capable of producing 2Mlbpa and the potential to be expanded to 3Mlbpa.
  - A revised contract book: Peninsula has successfully cancelled 5 of its 6 existing offtake contracts. These legacy contracts were at a uranium price of approximately US\$60/lb which created a financial liability for Peninsula and were creating unnecessary pressure on the development team to rush production timetables to meet the contract delivery obligations. Peninsula now has greater exposure to a high and rising uranium price.
  - An improved balance sheet: The \$70m capital raise means Peninsula is fully funded through Horizon 1 and Horizon 2. It will need additional capital to expand into Horizon 3, but by that stage the company is likely to attract strong support from debt financiers and the US government.
- We recently visited the Lance Project and witnessed the first uranium being produced. Peninsula formally announced first production on 16 Sept 2025, which we consider to be an excellent result just 14mths after construction of the Central Processing Plant (CPP) commenced. At the site visit, we also witnessed the development of Mine Unit 4 (MU-4) which will become the primary source of uranium production in 2026.
- In this report we update our forecasts and valuation for the new lower production profile, revised contract book with higher achieved pricing, and capital structure.

Peninsula revisions		2025f			2026f			2027f		2028f			
	New	Old	Chg %	New	Old	Chg %	New	Old	Chg %	New	Old	Chg %	
Production (klb)	0	0	n/a	400	800	-50%	600	1,300	-54%	1,200	1,700	-29%	
Revenue (A\$m)	0	0	n/a	38	52	-28%	87	111	-21%	172	172	0%	
EBITDA (A\$m)	-25	-25	0%	3	13	-76%	45	58	-22%	103	102	1%	
EBIT (A\$m)	-25	-25	0%	-2	4	-140%	38	45	-14%	89	85	5%	
NPAT (A\$m)	-23	-23	0%	-2	4	-159%	39	44	-13%	90	85	6%	
EPS (Acps)	-1	-1	0%	-1	2	-141%	10	20	-51%	23	39	-41%	

## Recommendation

We upgrade our recommendation to BUY with a price target of A\$1.33 (up from A\$1.00) based on our DCF valuation of the Lance Project.



**Peninsula Energy** Energy


Energy FactSet: PEN-AU / Bloomberg: PEN AU

Key Items	<u>Data</u>
Recommendation	BUY
Risk	HIGH
Price (\$ps)	0.39
Target Price (\$ps)	1.33
52 Week Range (\$ps)	0.28 - 1.56
Shares on Issue (m)	378
Market Cap (\$m)	146
Enterprise Value (\$m)	62
TSR (%)	246.6%

### **Company Description**

Peninsula Energy is an ASX listed company that owns the Lance Uranium Project in Wyoming, USA which is converting from an alkaline to a low-pH in-situ recovery operation. The Lance Project is restarting operations and produced its first uranium in September 2025. Lance has the potential to become the largest source of domestic uranium production in the US and is therefore a highly strategic asset  $\,$ in the context of the US nuclear fuel supply chain.





Financial Year End: 30 June					
Investment Summary (USD)	FY23A	FY24A	FY25E	FY26E	FY27E
EPS (Reported) (cps)	(0.3)	(0.6)	(1.3)	(0.8)	9.9
EPS (Underlying) (cps)	(0.3)	(0.6)	(1.3)	(0.8)	9.9
EPS (Underlying) Growth (%)	23.3%	(79.2%)	nm	44.0%	nm
PE (Underlying) (x)	nm	nm	(18.9)	(33.7)	2.6
EV / EBIT (x)	(21.2)	(3.4)	(1.7)	(25.1)	1.1
EV / EBITDA (x)	(21.2)	(3.4)	(1.7)	13.8	0.9
DPS (cps) (AUD)	0.0	0.0	0.0	0.0	0.0
Dividend Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Franking (%)	0%	0%	0%	0%	0%
Payout Ratio (%)	0.0% (0.4%)	0.0%	0.0%	0.0% (36.0%)	0.0% 26.4%
Free Cash Flow Yield (%)	` ,	(1.2%)	(23.0%)	, ,	
Profit and Loss (USD) (m)	FY23A	FY24A	FY25E	FY26E	FY27E
Sales	40	12	(100.00()	38	87
Sales Growth (%)	120.8%	(70.6%)	(100.0%)	n/a	132.0%
Other Operating Income EBITDA	0	1 (12)	1 (25)	1 <b>3</b>	1 <b>45</b>
EBITDA  EBITDA Margin (%)	<b>(4)</b> (11.0%)	( <b>12)</b> nm	( <b>25)</b> nm	8.1%	52.2%
Depreciation & Amortisation	(11.0%)	0	0	(5)	(7)
EBIT	(4.4)	(12.4)	(24.5)	(1.7)	38.3
EBIT Margin (%)	(11.0%)	nm	nm	(4.5%)	44.0%
Net Interest	0	0	2	(0)	0
Pretax Profit	(4)	(12)	(23)	(2)	39
Minorities	0	0	0	0	0
NPAT Underlying	(4)	(12)	(23)	(2)	39
Significant Items	0	0	0	Ó	0
NPAT Reported	(4)	(12)	(23)	(2)	39
Cashflow (USD) (m)	FY23A	FY24A	FY25E	FY26E	FY27E
EBIT	(4)	(12)	(25)	(2)	38
Tax Paid	0	0	0	0	0
Net Interest	0	1	2	(0)	0
Change in Working Capital	0	0	(10)	2	(12)
Depreciation & Amortisation	0	0	0	5	7
Other	9	16	0	0	0
Operating Cashflow	5	5	(32)	5	34
Capex	(12)	(33)	(66)	(30)	(8)
Acquisitions and Investments	0	0	0	0	0
Disposal of Fixed Assets/Investments	0	0	0	0	0
Other	(0)	0	0	0	0
Investing Cashflow	(12)	(33)	(66)	(30)	(8)
Free Cashflow	(7)	(28)	(98)	(25)	26
Equity Raised / Bought Back	21 0	106	0	45	0
Dividends Paid	0	0	0 15	(15)	0
Change in Debt Other	0	0	0	(15) 0	0
Financing Cashflow	21	<b>106</b>	15	<b>30</b>	0
Exchange Rate Effect	0	0	0	0	0
Net Change in Cash	14	78	(83)	5	26
•					
Balance Sheet (USD) (m) Cash	<b>FY23A</b>	<b>FY24A</b>	<b>FY25E</b>	FY26E	FY27E 48
Accounts Receivable	1	2	0	3	7
Inventory	12	2	10	6	14
Other Current Assets	0	0	0	0	0
PPE	24	35	68	90	90
Total Assets	62	146	102	128	166
Accounts Payable	4	5	1	2	3
Short Term Debt	0	0	15	0	0
Long Term Debt	0	0	0	0	0
Total Liabilities	16	18	29	15	16
Total Shareholder Equity	91	185	163	206	244
Ratios	FY23A	FY24A	FY25E	FY26E	FY27E
ROE (%)	(4.2%)	(8.9%)	(12.9%)	(1.1%)	17.1%
Gearing (%)	(30.3%)	(115.6%)	(1.2%)	(11.7%)	(24.3%)
Net Debt / EBITDA (x)	4.8	8.0	0.1	(7.1)	(1.1)

22.6

Price to Book (x)

17.9

0.2

0.5

0.4



Horizon 3

## Lance Uranium Project - revised production profile

Lance is an In-Situ Recovery (ISR) uranium project whereby uranium is leached from the orebody in an acid solution before being recovered in an ion-exchange resin.

The production profile of Lance has been 'reset' significantly lower than initial forecasts, which we suspect were being optimistically set to deliver into the contract book. The new forecasts appear to be more realistic and conservative.

Production is now being considered over three time horizons:

- Horizon 1: The initial commissioning phase of the project with production in CY25 of 'up to 50klb'.
- Horizon 2: The ramp-up phase through 2026 and 2027 with production in CY26 expected to be 400-500klb and in CY27 500-600klb. Those forecasts are conservative and have been informed by the low flow rates experienced in Mine-Unit-3 (MU-3). The guidance is based on production from MU-4 at a rate of 12GPM, given the higher permeability of the orebody in MU-4 it is possible that this flowrate could be reach 16GPM.
- Horizon 3: Full scale production from 2028. Guidance has been set at 1.2-1.5Mlb, but again that appears to be conservative with the plant capable of producing 2Mlbpa. We expect to see higher production rates than guidance and model the operation reaching 1.8Mlpa from 2030.

**Figure 1: Revised Production Estimates** 

## Reset / Commissioning

Operations CY2025
Focus on acidification of wellfields

## Ramp-Up 400,000 - 600,000lbs pa

Production CY2026 & CY2027 from January 2026 to December 2027

## 1,000,000 - 1,400,000lbs

Inventory of uranium recoverable under pattern from operating wellfields within MU-1,3 and 4 at end 31 Dec 2027

**Full Scale Production** 1.2Mlb - 1.5Mlbs p.a. Horizon 2 Ramp-Up 400,000 -Subject to 600,000lbs p.a FID / funding Horizon 1 Reset Plan Commissioning 2028 + Jan 2026 Jan 2028 Jun 2025

Source: Peninsula presentation – Sept 2025

Figure 2: Revised Production Plan Framework

# Horizon 1 Reset / Commissioning

### **FOCUS**

- Establishing the revised near-term production plan
- De-risking operational challenges
- CPP commissioning
- Financing
- Mining from MU-1 and MU-3
- · Production Guidance:
  - CY25 Up to 50,000 lbs
- First production of dry yellowcake

# Horizon 2 Ramp-Up

### **FOCUS**

- Focus on MU-3 and MU-4 optimisation
- Implementation of new HH patterns in MU-4
- Kendrick optimisation plan
- Dagger Scoping Study
- Mining from MU-1, MU-3 and MU-4
- · Production Guidance:
  - CY26 400,000 500,000 lbs
  - CY27 500,000 600,000 lbs
- Expected cash operating costs of US\$20M to US\$25M p.a. at the upper end of production guidance
- Projected positive cashflow from operations

# Horizon 3 Full Scale Production

### **FOCUS**

- LOM model to be updated in 2026, incorporating operating data from MU-3 and MU-4
- Financial Investment Decision including funding requirements (e.g. traditional debt, US Government debt)
- · Kendrick comes online
- Dagger and Barber development
- Targeting C1 cash costs of US\$30 to US\$35/lb
- Targeting 1.2Mlbs to 1.5Mlbs annual production from Ross and Kendrick

Source: Peninsula presentation - Sept 2025



### **Contract Book Reset**

As part of the reset, Peninsula successfully terminated five out of a total of six contracts across the group, completing the reset of the offtake contract book, and significantly derisking the business.

One sales contract remains in place, comprising of a take-or-pay obligation to deliver 600,000lbs U3O8, with annual deliveries of 100,000lbs U3O8 over the period 2028 to 2033 inclusive. The pricing structure is a blended approach including both base price (escalated) and market-price components. The Company has the right to terminate this contract early, on or before 31 December 2027 by making a termination payment.

The maximum consideration for the contracts that have been terminated totalling 5.14Mlbs U3O8 is US\$6.6 million. US\$1.6 million has already been paid with the remaining US\$5 million expected to be paid this quarter.

We understand that most of the cost of termination is related to near term delivery obligations in 2025, with minimal cost to reset the longer dated contracts.

Peninsula intends to re-engage with its former customers once the project has established a consistent track record as a reliable producer of dry yellowcake.

The names of the utility counterparties have not been disclosed.




Figure 3: Revised contract book

Source: PEN ASX release July 2025



## **Peninsula Financials**

We have remodelled Peninsula for the updated information in the reset plan. The key changes include:

- Updated production profile which matches the low end of Peninsula's guidance until 2030, and then 1.8Mlb from 2030 onwards.
- Updated contract book which results in higher achieved pricing more linked to spot prices.
- The higher share count from the \$70m capital raise which has increased shares on issue from 160m to 378m.

Figure 4: Peninsula P&L (US\$m)

Profit & Loss (US\$m)	2019	2020	2021	2022	2023	2024	2025f	2026f	2027f	2028f	2029f	2030f	2031f
U3O8 (Mlb) - produced	125	31	0	0	0	0	0	400	600	1,200	1,500	1,800	1,800
U308 (Mlb) - sold	205	191	300	450	750	200	0	400	600	1,200	1,500	1,800	1,800
Spot Uranium (US\$/Ib)	26	28	31	46	51	86	75	94	145	150	145	125	107
Peninsula achieved (US\$/Ib)	40	39	41	53	51	86	75	94	145	143	140	122	105
Revenue	7	6	10	18	40	12	0	38	87	172	210	219	189
Operating costs		-6	-9	-15	-39	-10	-10	-26	-33	-59	-75	-87	-86
Admin & other expenses	-44	-2	-2	-9	-6	-14	-15	-9	-9	-9	-9	-10	-10
Total costs	-44	-8	-11	-24	-45	-24	-25	-34	-42	-68	-84	-97	-96
EBITDA	-37	-2	-1	-6	-4	-12	-25	3	45	103	126	122	93
Depreciation & Amortisation	0	0	0	0	0	0	0	-5	-7	-14	-18	-21	-21
EBIT	-37	-2	-1	-6	-4	-12	-25	-2	38	89	108	101	72
Net Finance Expense	-3	-4	0	0	0	0	2	0	0	1	2	4	5
Profit before tax	-41	-6	-1	-6	-4	-12	-23	-2	39	90	110	105	78
Income tax (expense)/benefit	0	-2	0	1	1	0	0	0	0	0	-33	-32	-23
Reported NPAT	-43	-7	-1	-5	-4	-12	-23	-2	39	90	77	74	54
Minorities	0	0	0	0	0	0	0	0	0	0	0	0	0
Attributable NPAT	-40	-8	-2	-4	-4	-12	-23	-2	39	90	77	74	54

Source: Company reports, Shaw and Partners analysis

Figure 5: Peninsula Cash flow (US\$m)

CASH FLOW (US\$m)	2019	2020	2021	2022	2023	2024	2025f	2026f	2027f	2028f	2029f	2030f	2031f
Operating activities													
Receipts from customers	8	7	3	33	42	12	0	38	87	172	210	219	189
Payments to suppliers and employe	-15	-14	-11	-31	-37	-8	-25	-34	-42	-68	-84	-97	-96
Income taxes paid	0	0	0	0	0	0	0	0	0	0	0	-33	-32
Working capital movement	0	0	-9	0	0	0	-10	2	-12	-19	-8	-1	7
Other	0	-1	0	0	0	1	2	0	0	1	2	4	5
Net cash flow from operating activities	-7	-8	-17	2	5	5	-32	5	34	86	120	92	75
Investing activities													
Payments for PPE	0	0	0	-1	-12	-33	-66	-30	-8	-16	-24	-29	-29
Other	2	0	0	0	0	0	0	0	0	0	0	0	0
Net cash flow from investing activities	2	0	0	-1	-12	-33	-66	-30	-8	-16	-24	-29	-29
Free cash flow	-8	-8	-17	1	-7	-28	-98	-25	26	70	96	63	45
Financing activities													
Net proceeds from issue of shares	0	31	11	0	21	106	0	45	0	0	0	0	0
Proceeds from borrowings	0	1	1	0	0	0	15	0	0	0	0	0	0
Repayments of borrowings	-1	-17	0	0	0	0	0	-15	0	0	0	0	0
Dividends paid	0	0	0	0	0	0	0	0	0	0	0	-8	-20
Other	-1	0	0	0	0	0	0	0	0	0	0	0	0
Net cash flow from financing activities	-1	15	12	0	21	106	15	30	0	0	0	-8	-20
Net increase/(decrease) in cash	-7	7	-6	1	14	78	-83	5	26	70	96	56	25

Source: Company reports, Shaw and Partners analysis



## Peninsula Financials at US\$80/lb uranium

Our expectation is for uranium prices to significantly strengthen over the next 2 years to reach US\$150/lb before pulling back to a long term equilibrium price of US\$90/lb next decade.

In the tables below we outline the Peninsula financials at US\$80/lb. In this scenario our valuation reduces to A\$0.64ps

Figure 6: Peninsula P&L (US\$m)

- 18 and													
Profit & Loss (US\$m)	2019	2020	2021	2022	2023	2024	2025f	2026f	2027f	2028f	2029f	2030f	2031f
U3O8 (Mlb) - produced	125	31	0	0	0	0	0	400	600	1,200	1,500	1,800	1,800
U3O8 (Mlb) - sold	205	191	300	450	750	200	0	400	600	1,200	1,500	1,800	1,800
Spot Uranium (US\$/Ib)	26	28	31	46	51	86	80	82	84	86	87	89	91
Peninsula achieved (US\$/Ib)	40	39	41	53	51	86	80	82	84	86	87	89	91
Revenue	7	6	10	18	40	12	0	33	50	103	131	161	165
Operating costs		-6	-9	-15	-39	-10	-10	-25	-29	-52	-67	-82	-83
Admin & other expenses	-44	-2	-2	-9	-6	-14	-15	-9	-9	-9	-9	-10	-10
Total costs	-44	-8	-11	-24	-45	-24	-25	-34	-38	-61	-76	-91	-93
EBITDA	-37	-2	-1	-6	-4	-12	-25	-1	12	41	55	70	71
Depreciation & Amortisation	0	0	0	0	0	0	0	-5	-7	-14	-18	-21	-21
EBIT	-37	-2	-1	-6	-4	-12	-25	-6	5	27	37	48	50
Net Finance Expense	-3	-4	0	0	0	0	2	0	0	0	1	1	2
Profit before tax	-41	-6	-1	-6	-4	-12	-23	-6	6	27	38	50	52
Income tax (expense)/benefit	0	-2	0	1	1	0	0	0	0	0	-11	-15	-16
Reported NPAT	-43	-7	-1	-5	-4	-12	-23	-6	6	27	27	35	36
Minorities	0	0	0	0	0	0	0	0	0	0	0	0	0
Attributable NPAT	-40	-8	-2	-4	-4	-12	-23	-6	6	27	27	35	36

Source: Company reports, Shaw and Partners analysis

Figure 7: Peninsula Cash flow (USSm)

CASH FLOW (US\$m)	2019	2020	2021	2022	2023	2024	2025f	2026f	2027f	2028f	2029f	2030f	2031f
Operating activities													
Receipts from customers	8	7	3	33	42	12	0	33	50	103	131	161	165
Payments to suppliers and employe	-15	-14	-11	-31	-37	-8	-25	-34	-38	-61	-76	-91	-93
Income taxes paid	0	0	0	0	0	0	0	0	0	0	0	-11	-15
Working capital movement	0	0	-9	0	0	0	-10	3	-4	-11	-6	-6	-1
Other	0	-1	0	0	0	1	2	0	0	0	1	1	2
Net cash flow from operating activities	-7	-8	-17	2	5	5	-32	2	9	31	50	53	57
Investing activities													
Payments for PPE	0	0	0	-1	-12	-33	-66	-30	-8	-16	-24	-29	-29
Other	2	0	0	0	0	0	0	0	0	0	0	0	0
Net cash flow from investing activities	2	0	0	-1	-12	-33	-66	-30	-8	-16	-24	-29	-29
Free cash flow	-8	-8	-17	1	-7	-28	-98	-28	1	15	26	25	28
Financing activities													
Net proceeds from issue of shares	0	31	11	0	21	106	0	45	0	0	0	0	0
Proceeds from borrowings	0	1	1	0	0	0	15	0	0	0	0	0	0
Repayments of borrowings	-1	-17	0	0	0	0	0	-15	0	0	0	0	0
Dividends paid	0	0	0	0	0	0	0	0	0	0	0	-4	-11
Other	-1	0	0	0	0	0	0	0	0	0	0	0	0
Net cash flow from financing activities	-1	15	12	0	21	106	15	30	0	0	0	-4	-11
Net increase/(decrease) in cash	-7	7	-6	1	14	78	-83	2	1	15	26	21	17

Source: Company reports, Shaw and Partners analysis



## **Key risks**

- As a small mining company broadly exposed to a single commodity and a single asset we consider an investment in Peninsula Energy to be high risk. The key risks include:
- The U3O8 market is relatively opaque and difficult to forecast. The actual uranium price may differ substantially from our forecasts.
- Operations for PEN are in the early stages of commissioning and there is a risk that they
  may be unable to bring Lance Projects to production in line with expectations. Costs
  may be higher and operations may not perform as expected.
- Resource risks PEN's 2022 Ross and Kendrick DFS assumes an overall resource recovery of 66% and a resource conversion of 61% to convert the Ross and Kendrick Area Inferred resources to Indicated or greater quality.
- Forecasting future operating costs has considerable uncertainty. Our forecasts may
  prove to be too optimistic. If each company's costs are higher than we expect then our
  cash flow forecasts will be too high.
- Smaller companies carry more significant 'key personnel' risk than larger organisations.
   If senior management depart it could delay projects or exacerbate operational risks.

### Core drivers and catalyst

- PEN's flagship Lance Projects in Wyoming, USA, is currently commissioning and produced its first yellowcake in September 2025.
- The uranium market is structurally undersupplied, a situation which is likely to be exacerbated by renewed growth in uranium demand as nuclear power returns to favour. Strong demand to decarbonise energy grids as well as demand for nuclear to power Al data centres is likely to see uranium prices move materially higher in coming years. We expect to see uranium reaching US\$150/lb this cycle before reverting to a long term equilibrium price of US\$90/lb next decade.
- The operation successfully produced its first U3O8 ("yellowcake") in September 2025 and is now ramping up to full capacity over the next three years. As Peninsula continues to demonstrate that the operation can efficiently produce uranium the stock is likely to re-rate.
- In our view there are two key advantages to PEN's project being located in Wyoming,
  USA: the Powder River Basin in Wyoming is in an established uranium and mining
  jurisdiction (uranium mining for ~70 years and coal mining for ~150 years), and the
  company may benefit from US government support.



## **Rating Classification**

Buy	Expected to outperform the overall market
Hold	Expected to perform in line with the overall market
Sell	Expected to underperform the overall market
Not Rated	Shaw has issued a factual note on the company but does not have a recommendation

## **Risk Rating**

High	Higher risk than the overall market – investors should be aware this stock may be speculative
Medium	Risk broadly in line with the overall market
Low	Lower risk than the overall market

RISK STATEMENT: Where a company is designated as 'High' risk, this means that the analyst has determined that the risk profile for this company is significantly higher than for the market as a whole, and so may not suit all investors. Clients should make an assessment as to whether this stock and its potential price volatility is compatible with their financial objectives. Clients should discuss this stock with their Shaw adviser before making any investment decision.

Distribution of Investment Ratings				
Rating	Count	Recommendation Universe		
Buy	81	87%		
Hold	12	13%		
Sell	0	0%		

History of Investment Rating and Target Price - Peninsula Energy					
Date	Closing Price (\$) Targe	et Price (\$)	Rating	\$6.0	
19-Sep-25	0.39	1.33	Buy	\$5.0	
4-Apr-25	0.49	0.74	Hold	\$4.0	
4-Jan-25	1.04	3.57	Buy	\$3.0 -	
5-Nov-24	0.92	3.58	Buy	\$2.0	
6-Oct-24	1.48	3.85	Buy	\$1.0	
8-May-24	1.63	3.83	Buy	\$0.0	
1-Apr-24	1.59	4.53	Buy	09/22 12/22 03/23 06/23 09/23 12/23 03/24 06/24 09/24 12/24 03/	
2-Jan-24	1.59	4.85	Buy	Peninsula Energy — Target Price	
7-Nov-23	1.52	3.60	Buy	Buy	
Nov-23	1.88	3.85	Buy	Day	
1-Aug-23	1.32	3.84	Buy	Hold	
9-Jul-23	1.88	4.45	Buy		
7-Jun-23	2.38	4.90	Buy		
-May-23	2.17	4.87	Buy		



## **Disclaimer**

Shaw and Partners Limited ABN 24 003 221 583 ("Shaw") is a Participant of ASX Limited, Cboe Australia Pty Limited and holder of Australian Financial Services Licence number 236048.

**ANALYST CERTIFICATION**: The Research Analyst who prepared this report hereby certifies that the views expressed in this document accurately reflect the analyst's personal views about the Company and its financial products. Neither Shaw nor its Research Analysts received any direct financial or non-financial benefits from the company for the production of this document. However, Shaw Research Analysts may receive assistance from the company in preparing their research which can include attending site visits and/or meetings hosted by the company. In some instances the costs of such site visits or meetings may be met in part or in whole by the company if Shaw considers it is reasonable given the specific circumstances relating to the site visit or meeting. As at the date of this report, the Research Analyst does not hold, either directly or through a controlled entity, securities in the Company that is the subject of this report, or where they do hold securities those interests are not material. Shaw restricts Research Analysts from trading in securities outside of the ASX/S&P100 for which they write research. Other Shaw employees may hold interests in the company, but none of those interests are material.

DISCLAIMER: This report is published by Shaw to its clients by way of general, as opposed to personal, advice. This means it has been prepared for multiple distribution without consideration of your investment objectives, financial situation and needs ("Personal Circumstances"). Accordingly, the advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not the advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of your Shaw client adviser. This report is provided to you on the condition that it not be copied, either in whole or in part, distributed to or disclosed to any other person. If you are not the intended recipient, you should destroy the report and advise Shaw that you have done so. This report is published by Shaw in good faith based on the facts known to it at the time of its preparation and does not purport to contain all relevant information with respect to the financial products to which it relates. The research report is current as at the date of publication until it is replaced, updated or withdrawn. Although the report is based on information obtained from sources believed to be reliable, Shaw does not make any representation or warranty that it is accurate, complete or up to date and Shaw accepts no obligation to correct or update the information or opinions in it. If you rely on this report, you do so at your own risk. Any projections are indicative estimates only and may not be realised in the future. Such projections are contingent on matters outside the control of Shaw (including but not limited to market volatility, economic conditions and company-specific fundamentals) and therefore may not be realised in the future. Past performance is not a reliable indicator of future performance. Except to the extent that liability under any law cannot be excluded, Shaw disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence.

Depending on the timing and size of your investment, your portfolio composition may differ to the model. Performance figures are derived from the inception date of the model and its investment transactions from that date, therefore the performance for your portfolio may be different. If you have any questions in connection with differences between your portfolio and the model, you should speak with your adviser.

For U.S. persons only: This research report is a product of Shaw and Partners Limited under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Shaw and Partners Limited has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.

**DISCLOSURE**: Shaw will charge commission in relation to client transactions in financial products and Shaw client advisers will receive a share of that commission. Shaw, its authorised representatives, its associates and their respective officers and employees may have earned previously or may in the future earn fees and commission from dealing in the Company's financial products. Shaw acted for the company in a corporate capacity within the past 12 months for which it received a fee.

Sydney   Head Office	Melbourne	Brisbane	Adelaide	Canberra	Perth	Noosa
Level 7, Chifley Tower	Level 36	Level 28	Level 25	Level 9	Level 47	Suite 11a Q Place
2 Chifley Square	120 Collins Street	111 Eagle Street	91 King William Street	5 Constitution Avenue	108 St Georges Terrace	2 Quamby Place
Sydney NSW 2000	Melbourne VIC 3000	Brisbane QLD 4000	Adelaide SA 5000	Canberra ACT 2601	Perth WA 6000	Noosa Heads QLD 4567
Telephone: +61 2 9238 1238	Telephone: +61 3 9268 1000	Telephone: +61 7 3036 2500	Telephone: +61 8 7109 6000	Telephone: +61 2 6113 5300	Telephone: +61 8 9263 5200	Telephone: +61 7 3036 2570
Toll Free: 1800 636 625	Toll Free: 1800 150 009	Toll Free: 1800 463 972	Toll Free: 1800 636 625	Toll Free: 1800 636 625	Toll Free: 1800 198 003	Toll Free: 1800 271 201